Speaker: Steven Julious, Medical Statistics Group, University of Sheffield
Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis
Co-author: Anne Whitehead
Pharmaceutical Statistics, Volume 11, Issue 1, Pages 49-56, January/February 2012 Abstract | Paper+ | Slides
Speaker: Christy Chuang-Stein, Pfizer
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Co-author: Mohan Beltangady
Pharmaceutical Statistics, Volume 10, Issue 1, Pages 3–7, January/February 2011 Abstract | Paper+ | Slides
+ Papers available to view from 11th April 2012 to 9th May 2012.
For a flier advertising the event, please click here.
Speaker: Steven Julious, Medical Statistics Group, University of Sheffield
Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis
Co-author: Anne Whitehead
Pharmaceutical Statistics, Volume 11, Issue 1, Pages 49-56, January/February 2012 Abstract | Paper+ | Slides
Speaker: Christy Chuang-Stein, Pfizer
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Co-author: Mohan Beltangady
Pharmaceutical Statistics, Volume 10, Issue 1, Pages 3–7, January/February 2011 Abstract | Paper+ | Slides
+ Papers available to view from 11th April 2012 to 9th May 2012.
For a flier advertising the event, please click here.
Speaker: Steven Julious, Medical Statistics Group, University of Sheffield
Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis
Co-author: Anne Whitehead
Pharmaceutical Statistics, Volume 11, Issue 1, Pages 49-56, January/February 2012 Abstract | Paper+ | Slides
Speaker: Christy Chuang-Stein, Pfizer
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Co-author: Mohan Beltangady
Pharmaceutical Statistics, Volume 10, Issue 1, Pages 3–7, January/February 2011 Abstract | Paper+ | Slides
+ Papers available to view from 11th April 2012 to 9th May 2012.
For a flier advertising the event, please click here.
Speaker: Steven Julious, Medical Statistics Group, University of Sheffield
Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis
Co-author: Anne Whitehead
Pharmaceutical Statistics, Volume 11, Issue 1, Pages 49-56, January/February 2012 Abstract | Paper+ | Slides
Speaker: Christy Chuang-Stein, Pfizer
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Co-author: Mohan Beltangady
Pharmaceutical Statistics, Volume 10, Issue 1, Pages 3–7, January/February 2011 Abstract | Paper+ | Slides
+ Papers available to view from 11th April 2012 to 9th May 2012.
For a flier advertising the event, please click here.
Speaker: Steven Julious, Medical Statistics Group, University of Sheffield
Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis
Co-author: Anne Whitehead
Pharmaceutical Statistics, Volume 11, Issue 1, Pages 49-56, January/February 2012 Abstract | Paper+ | Slides
Speaker: Christy Chuang-Stein, Pfizer
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Co-author: Mohan Beltangady
Pharmaceutical Statistics, Volume 10, Issue 1, Pages 3–7, January/February 2011 Abstract | Paper+ | Slides
+ Papers available to view from 11th April 2012 to 9th May 2012.
For a flier advertising the event, please click here.
Speaker: Steven Julious, Medical Statistics Group, University of Sheffield
Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis
Co-author: Anne Whitehead
Pharmaceutical Statistics, Volume 11, Issue 1, Pages 49-56, January/February 2012 Abstract | Paper+ | Slides
Speaker: Christy Chuang-Stein, Pfizer
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Co-author: Mohan Beltangady
Pharmaceutical Statistics, Volume 10, Issue 1, Pages 3–7, January/February 2011 Abstract | Paper+ | Slides
+ Papers available to view from 11th April 2012 to 9th May 2012.
For a flier advertising the event, please click here.
Upcoming Events
PSI VisSIG Wonderful Wednesday Webinar Series (2023)
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
PSI Launch & Lifecycle SIG Webinar: Do you want to stay single? Considerations on single arm trials in the post-regulatory space
We will present the most frequently asked questions in the post-marketing space, the reasons why SATs are not able to address these questions, and how statisticians might reasonably influence decision makers to consider alternatives.
PSI Scientific Meeting: Patient-focused drug development
The meeting will consider the importance of patient-centric input into regulatory and HTA decision-making discussing the latest developments in the field and presenting industry examples.
PSI Pre-Clinical SIG Webinar: Adjusting Experimental & Statistical Approaches throughout Preclinical development pathways
PD Dr. Tölch will present a framework to foster efficient evidence generation in preclinical experiments and will illustrate the proposed approach using examples from various projects. This will be followed by Q&A.
PSI Vaccine SIG Webinar: A Vaccine Statistician’s Journey in Designing and Analyzing Monoclonal Antibody Studies
Our speaker will share her experience in extending/innovating methodology and concepts developed in vaccine statistics to the analyses of pre-efficacy and efficacy trials of monoclonal antibodies.
PSI Training Course: Sample Sizing for Clinical Trials
This course describes calculations for sample size estimation in the design of clinical trials. It will highlight how the objectives of a clinical trial will impact on sample size calculations. The course is a practical course and all methods will be illustrated with examples and case studies.
PSI Biomarkers SIG Webinar: A promising adaptive biomarker-based design strategy for early phase and machine learning as an enabler of precision medicine!
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
This one-day event will establish a forum to engage with colleagues from a diverse range of backgrounds who are actively working on effective master protocol design, analysis, and execution.
This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Webinar(s): Causal inference in Clinical Trials
Over the course of two sessions, a panel of 8 esteemed speakers will give an introduction to the topic, followed by a presentation of case studies & interactive panel discussion.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK